Predicting progression in the late onset frontal lobe syndrome.


Journal

International psychogeriatrics
ISSN: 1741-203X
Titre abrégé: Int Psychogeriatr
Pays: England
ID NLM: 9007918

Informations de publication

Date de publication:
05 2019
Historique:
pubmed: 27 10 2018
medline: 10 3 2020
entrez: 27 10 2018
Statut: ppublish

Résumé

ABSTRACTA late onset frontal lobe syndrome (LOF) refers to a clinical syndrome with apathy, disinhibition, or stereotypical behavior arising in middle or late adulthood. Diagnostics are challenging, and both clinicians and patients need reliable predictors of progression to improve clinical guidance. In this longitudinal multicenter and genetically screened prospective study, 137 LOF patients with frontal behavior (FBI score≥11) and/or stereotypical behavior (SRI≥10) were included. Progression was defined as institutionalization, death, or progression of frontal or temporal atrophy at magnetic resonance imaging (MRI) after two years of follow up. Absence of progression at MRI in addition to stable or improved Mini Mental State Examination and Frontal Assessment Battery scores after two years was indicative for non-progression. The presence of stereotypy and a neuropsychological profile with executive deficits at baseline were found to be predictive for progression, while a history and family history with psychiatric disorders were predictors for non-progression. The combination of these clinical markers had a predictive value of 80.4% (p < 0.05). In patients presenting with late onset behavioral symptoms, an appraisal of the rate of deterioration can be made by detailed mapping of clinical symptoms. Distinction of progressive discourses from non-progressive or treatable conditions is to be gained.

Identifiants

pubmed: 30362933
pii: S1041610218001242
doi: 10.1017/S1041610218001242
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

743-748

Auteurs

Flora T Gossink (FT)

Department of Old Age Psychiatry,GGZinGeest/VU University Medical Center,Amsterdam,the Netherlands.

Everard Vijverberg (E)

Alzheimer Centre & Department of Neurology,VU University Medical Center,Amsterdam,the Netherlands.

Welmoed Krudop (W)

Alzheimer Centre & Department of Neurology,VU University Medical Center,Amsterdam,the Netherlands.

Philip Scheltens (P)

Alzheimer Centre & Department of Neurology,VU University Medical Center,Amsterdam,the Netherlands.

Max L Stek (ML)

Department of Old Age Psychiatry,GGZinGeest/VU University Medical Center,Amsterdam,the Netherlands.

Yolande A L Pijnenburg (YAL)

Department of Old Age Psychiatry,GGZinGeest/VU University Medical Center,Amsterdam,the Netherlands.

Annemiek Dols (A)

Department of Old Age Psychiatry,GGZinGeest/VU University Medical Center,Amsterdam,the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH